Viral Vectors for Non human Primates Market Size to Hit USD 397.87 Mn by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Viral Vectors for Non-human Primates Market

5.1. COVID-19 Landscape: Viral Vectors for Non-human Primates Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Viral Vectors for Non-human Primates Market, By Vector Type

8.1. Viral Vectors for Non-human Primates Market Revenue and Volume, by Vector Type

8.1.1. Adenoviral Vectors

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Adeno-associated Vectors

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Retroviral Vectors

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Lentiviral Vectors

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Viral Vectors for Non-human Primates Market, By Type of Non-human Primates

9.1. Viral Vectors for Non-human Primates Market Revenue and Volume, by Type of Non-human Primates

9.1.1. Marmosets

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Rhesus Macaques

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Cynomolgus Monkey

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Others

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Viral Vectors for Non-human Primates Market, By Application

10.1. Viral Vectors for Non-human Primates Market Revenue and Volume, by Application

10.1.1. Gene Therapy

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Vaccine Research

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Viral Vectors for Non-human Primates Market, By Therapeutic Area

11.1. Viral Vectors for Non-human Primates Market Revenue and Volume, by Therapeutic Area

11.1.1. Genetic Disorders

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Infectious Diseases Oncological Disorders

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Oncological Disorders

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Viral Vectors for Non-human Primates Market, By End-user

12.1. Viral Vectors for Non-human Primates Market Revenue and Volume, by End-user

12.1.1. Pharmaceutical and Biotechnology Companies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Academic and Research Institutes

12.1.2.1. Market Revenue and Volume Forecast

Chapter 13. Global Viral Vectors for Non-human Primates Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Vector Type

13.1.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.1.3. Market Revenue and Volume Forecast, by Application

13.1.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.1.5. Market Revenue and Volume Forecast, by End-user

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Vector Type

13.1.6.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.1.6.3. Market Revenue and Volume Forecast, by Application

13.1.6.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.1.6.5. Market Revenue and Volume Forecast, by End-user

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Vector Type

13.1.7.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.1.7.3. Market Revenue and Volume Forecast, by Application

13.1.7.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.1.7.5. Market Revenue and Volume Forecast, by End-user

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Vector Type

13.2.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.2.3. Market Revenue and Volume Forecast, by Application

13.2.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.2.5. Market Revenue and Volume Forecast, by End-user

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Vector Type

13.2.6.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.2.6.3. Market Revenue and Volume Forecast, by Application

13.2.7. Market Revenue and Volume Forecast, by Therapeutic Area

13.2.8. Market Revenue and Volume Forecast, by End-user

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Vector Type

13.2.9.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.2.9.3. Market Revenue and Volume Forecast, by Application

13.2.10. Market Revenue and Volume Forecast, by Therapeutic Area

13.2.11. Market Revenue and Volume Forecast, by End-user

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Vector Type

13.2.12.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.2.12.3. Market Revenue and Volume Forecast, by Application

13.2.12.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.2.13. Market Revenue and Volume Forecast, by End-user

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Vector Type

13.2.14.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.2.14.3. Market Revenue and Volume Forecast, by Application

13.2.14.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.2.15. Market Revenue and Volume Forecast, by End-user

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Vector Type

13.3.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.3.3. Market Revenue and Volume Forecast, by Application

13.3.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.3.5. Market Revenue and Volume Forecast, by End-user

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Vector Type

13.3.6.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.3.6.3. Market Revenue and Volume Forecast, by Application

13.3.6.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.3.7. Market Revenue and Volume Forecast, by End-user

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Vector Type

13.3.8.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.3.8.3. Market Revenue and Volume Forecast, by Application

13.3.8.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.3.9. Market Revenue and Volume Forecast, by End-user

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Vector Type

13.3.10.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.3.10.3. Market Revenue and Volume Forecast, by Application

13.3.10.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.3.10.5. Market Revenue and Volume Forecast, by End-user

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Vector Type

13.3.11.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.3.11.3. Market Revenue and Volume Forecast, by Application

13.3.11.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.3.11.5. Market Revenue and Volume Forecast, by End-user

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Vector Type

13.4.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.4.3. Market Revenue and Volume Forecast, by Application

13.4.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.4.5. Market Revenue and Volume Forecast, by End-user

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Vector Type

13.4.6.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.4.6.3. Market Revenue and Volume Forecast, by Application

13.4.6.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.4.7. Market Revenue and Volume Forecast, by End-user

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Vector Type

13.4.8.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.4.8.3. Market Revenue and Volume Forecast, by Application

13.4.8.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.4.9. Market Revenue and Volume Forecast, by End-user

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Vector Type

13.4.10.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.4.10.3. Market Revenue and Volume Forecast, by Application

13.4.10.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.4.10.5. Market Revenue and Volume Forecast, by End-user

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Vector Type

13.4.11.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.4.11.3. Market Revenue and Volume Forecast, by Application

13.4.11.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.4.11.5. Market Revenue and Volume Forecast, by End-user

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Vector Type

13.5.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.5.3. Market Revenue and Volume Forecast, by Application

13.5.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.5.5. Market Revenue and Volume Forecast, by End-user

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Vector Type

13.5.6.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.5.6.3. Market Revenue and Volume Forecast, by Application

13.5.6.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.5.7. Market Revenue and Volume Forecast, by End-user

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Vector Type

13.5.8.2. Market Revenue and Volume Forecast, by Type of Non-human Primates

13.5.8.3. Market Revenue and Volume Forecast, by Application

13.5.8.4. Market Revenue and Volume Forecast, by Therapeutic Area

13.5.8.5. Market Revenue and Volume Forecast, by End-user

Chapter 14. Company Profiles

14.1. Merck KGaA

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. 4D Molecular Therapeutics

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Barinthus Biotherapeutics

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Biovian Oy

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Andelyn Biosciences

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Lonza Group AG

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Fujifilm Diosynth Biotechnologies

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. CRISPR Therapeutics

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Oxford Biomedica

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. REGENXBIO Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global viral vectors for non-human primates market is expected to increase from USD 145.8 million in 2024 to USD 397.87 million by 2034.

The viral vectors for non-human primates marketis expected to grow at a compound annual growth rate (CAGR) of around 10.56% from 2025 to 2034.

The major players in the viral vectors for non-human primates market include Merck KGaA, 4D Molecular Therapeutics, Barinthus Biotherapeutics, Biovian Oy, Andelyn Biosciences, Lonza Group AG, Fujifilm Diosynth Biotechnologies, CRISPR Therapeutics, Oxford Biomedica, and REGENXBIO Inc.

The driving factors of the viral vectors for non-human primates market are the increased prevalence of genetic disorders, infectious diseases, and cancers is driving demand for the production of viral vectors to use in non-human clinical trials

North America region will lead the global viral vectors for non-human primates market during the forecast period 2025 to 2034.